Effects of the Selective Stretch-Activated Channel Blocker GsMtx4 on Stretch-Induced Changes in Refractoriness in Isolated Rat Hearts and on Ventricular Premature Beats and Arrhythmias after Coronary Occlusion in Swine

José A. Barrabés*, Javier Inserte, Luis Agulló, Antonio Rodríguez-Sinovas, Juan J. Alburquerque-Béjar, David Garcia-Dorado

Servicio de Cardiología, Hospital Universitari Vall d’Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain

* jabarrabes@vhebron.net

Abstract

Mechanical factors may contribute to ischemic ventricular arrhythmias. GsMtx4 peptide, a selective stretch-activated channel blocker, inhibits stretch-induced atrial arrhythmias. We aimed to assess whether GsMtx4 protects against ventricular ectopy and arrhythmias following coronary occlusion in swine. First, the effects of 170-nM GsMtx4 on the changes in the effective refractory period (ERP) induced by left ventricular (LV) dilatation were assessed in 8 isolated rat hearts. Then, 44 anesthetized, open-chest pigs subjected to 50-min left anterior descending artery occlusion and 2-h reperfusion were blindly allocated to GsMtx4 (57 μg/kg iv. bolus and 3.8 μg/kg/min infusion, calculated to attain the above concentration in plasma) or saline, starting 5-min before occlusion and continuing until after reflow. In rat hearts, LV distension induced progressive reductions in ERP (35 ± 2, 32 ± 2, and 29 ± 2 ms at 0, 20, and 40 mmHg of LV end-diastolic pressure, respectively, P < 0.001) that were prevented by GsMTx4 (33 ± 2, 33 ± 2, and 32 ± 2 ms, respectively, P = 0.002 for the interaction with LV end-diastolic pressure). Pigs receiving GsMtx4 had similar number of ventricular premature beats during the ischemic period as control pigs (110 ± 28 vs. 103 ± 21, respectively, P = 0.842). There were not significant differences among treated and untreated animals in the incidence of ventricular fibrillation (13.6 vs. 22.7%, respectively, P = 0.696) or tachycardia (36.4 vs. 50.0%, P = 0.361) or in the number of ventricular tachycardia episodes during the occlusion period (1.8 ± 0.7 vs. 5.5 ± 2.6, P = 0.323). Thus, GsMtx4 administered under these conditions does not suppress ventricular ectopy following coronary occlusion in swine. Whether it might protect against malignant arrhythmias should be tested in studies powered for these outcomes.
Introduction

Malignant ventricular arrhythmias are frequent and life-threatening complications of acute myocardial ischemia. While the mechanisms of ischemic arrhythmias are complex and not completely understood [1,2], the potential contribution of mechanical factors is progressively gaining recognition [3,4]. On the one hand, these arrhythmias are often initiated by ventricular premature beats (VPBs) originated at the ischemic border [5–7], an area of increased mechanical tension. On the other hand, the border zone modulates the distribution of wave breaks during ventricular fibrillation, regional ischemia increasing wave break incidence at this zone [8,9]. Finally, spontaneous [10–13], induced [6,14], or simulated [7] left ventricular distension has been associated with an increased arrhythmogenicity following coronary occlusion.

Mechanically-induced arrhythmias have been suppressed in different experimental preparations not involving ischemia by gadolinium or other blockers of stretch-activated ion channels (SACs) [15–19]. However, attempts to protect against ventricular arrhythmias after coronary occlusion in vivo with intravenous [11] or intracoronary [12] gadolinium have failed. While this failure might reflect the absence of a significant contribution of SACs to ischemic ventricular arrhythmias, it may also have been due in part to the limited bioavailability of gadolinium [20].

GsMtx4, a peptide isolated from tarantula venom that selectively inhibits SACs [21] and that has effectively suppressed stretch-induced atrial fibrillation in perfused rabbit hearts [22] might circumvent this limitation. Our aim was to assess whether GsMtx4 peptide, administered intravenously prior and during ischemia, would reduce ventricular ectopy and the number and severity of arrhythmias during coronary occlusion in anesthetized swine.

Materials and Methods

The experimental protocol was approved by the Ethical Committee on Animal Experimentation of Vall d’Hebron Research Institute (ref. CEEA 25/05). GsMtx4 peptide was synthesized (21st Century Biochemicals, Marlboro, MA) as previously described [23]. As determined by high-performance liquid chromatography, the purity of the linear peptide was 97.7%. After synthesis, the peptide was folded by reduction with glutathione as previously described [23].

Experiments in isolated rat hearts

Experimental preparation and monitoring. These experiments were aimed to confirm that the synthesized peptide was biologically active against stretch-induced electrophysiological changes. Eight male Sprague-Dawley rats (300–350 g) were anesthetized with intraperitoneal sodium pentobarbital (100 mg/kg). Hearts were mounted into a non-recirculating Langendorff apparatus, and perfused at 10 ml/min with modified Krebs-Henseleit bicarbonate buffer equilibrated with 95% O2/5% CO2 as previously described [24]. A fluid-filled latex balloon was introduced into the left ventricle (LV) to monitor intraventricular pressure. Two hook electrodes were implanted approximately 3-mm apart over the mid anterior aspect of the LV. LV-developed pressure was calculated as the difference between LV systolic pressure and LV end-diastolic pressure (LVEDP). Perfusion pressure was continuously recorded. These signals, along with the electrogram, were acquired, digitized, and measured using a 16-channel PowerLab system (ADInstruments, Bella Vista, Australia).

Determination of the effective refractory period and arrhythmia inducibility and their modification by changing the loading conditions and by GsMtx4. Hearts were paced at a 250-ms cycle length (UHS-20 stimulator, Biotronik, Berlin, Germany). Programmed bipolar stimulation was performed to determine the effective refractory period (ERP). After a drive train of 20x200 ms, a ventricular extrastimulus was introduced with an initial coupling interval
of 15-ms that was progressively increased at 1-ms steps until capture was observed twice in a row. The ERP was defined as the highest coupling interval failing to capture. The stimulation protocol was continued until reaching a coupling interval of 5-ms above the ERP and the number of episodes of induced ventricular tachycardia in these 5 runs was counted and their duration recorded (Fig 1).

These measurements were performed in each heart at 3 different values of LVEDP: 0, 20 and 40 mmHg, in random order. LVEDP was modified by changing the volume of fluid in the balloon. Measurements were performed sequentially with and without GsMtx4 in the perfusate, also in a random order and in a blinded fashion. During the first set of measurements, a solution containing GsMtx4 or only the buffer was added through a lateral line, and the second set of measurements was repeated after 30-min washout by adding the complementary solution. GsMtx4 was infused at a final concentration of 170 nM, which suppressed stretch-induced atrial arrhythmias ex-vivo [22]. The 30-min washout time also proved to ensure the complete disappearance of GsMtx4 effects [22].
Experiments in pigs subjected to coronary occlusion

**Animal preparation.** Forty-six domestic hybrid pigs of either sex (33±1 kg) were premedicated with 10 mg/kg intramuscular azaperone and anesthetized with 30 mg/kg intravenous thiopental sodium followed by a continuous infusion. We previously observed in this animal model that the dilatation of the ischemic region was associated with ventricular fibrillation or tachycardia after coronary occlusion [10–13]. Animals were intubated and mechanically ventilated. One femoral artery and vein were catheterized, a sternotomy was performed and the pericardium was opened. The mid left anterior descending artery (LAD) was dissected and surrounded by a snare, adjacent to which a Doppler flow probe was placed. Two pairs of ultrasonic crystals were inserted into the LV wall, along a plane perpendicular to the long axis of the ventricle, one pair in the myocardium to be made ischemic and the other in the lateral wall. A micromanometer-tipped catheter (Mikro-tip, Millar, Houston, TX) was inserted into the LV.

**Experimental protocol and postmortem studies.** After attaining hemodynamic stability, the LAD was occluded by tightening the snare. Animals were blindly allocated to receive GsMtx4 or saline. In the former group, a saline solution containing 57.4 μg GsMtx4/kg was administered intravenously during 2 min starting 5 min before coronary occlusion (a blood concentration of 200-nM GsMTx4 was estimated assuming a molecular weight of 4.1 KDa, a purity of 97.7% and a blood volume of 70 mL/kg). After this bolus, a maintenance infusion of 3.8 μg/kg/min was provided during the following 58 min. Fifty minutes after coronary occlusion, reperfusion was allowed for 2 hours, after which time the LAD was re-occluded. Animals were euthanized by pentobarbital overdose followed if needed by inducing ventricular fibrillation. The heart was excised and cut in slices and the mass of the ischemic region (in vivo fluorescein injection) and infarct size (triphenyltetrazolium chloride reaction) were calculated as previously described [10–13].

Two animals were excluded, one before randomization due to major bleeding during sternotomy and one after randomization due to incessant ventricular fibrillation immediately after coronary occlusion, showing the examination of the heart severe subaortic stenosis and LV hypertrophy. Thus, this series was composed of 44 valid experiments, 22 in each treatment arm.

**Study monitoring.** Serial arterial blood gases were obtained to adjust the ventilator parameters. Serum pH, sodium, potassium, and bicarbonate levels and the hematocrit value were measured at baseline and at the end of the experiment. Aortic pressure was monitored. The ultrasonic signals were analyzed with an ultrasonic dimension system (System 6/200, Triton Technology, San Diego, CA) and monitored with an oscilloscope (HM 205–3, Hameg, Frankfurt, Germany). These signals, along with an electrocardiographic lead, aortic pressure, LAD blood flow and LV pressure and its first derivative (dP/dt) were continuously recorded, digitized (ML795 PowerLab) and stored (Fig 2). If ventricular fibrillation occurred, the heart was defibrillated with 10–20 J shocks.

In 12 animals (6 per group), the ventricular ERP was determined by programmed stimulation, as previously described [13], before and after bolus administration of GsMtx4 or placebo.

**Segment length measurements and ventricular arrhythmias.** Segment length measurements were performed on the digital records as previously described [10–13]. End-diastolic and end-systolic segment lengths (EDL, ESL) and maximal segment length were measured at several time points. Systolic shortening was calculated as follows (%): (EDL–ESL)x100/EDL. EDL was expressed as a percentage of values before coronary occlusion. Systolic bulging was defined as the ratio of maximal segment length during systole and EDL of the same beat times 100%. The number of VPBs during the occlusion period was counted and the occurrence of ventricular tachycardia (≥3 consecutive ventricular beats) or fibrillation was recorded. Only the initiating ventricular beat of ventricular tachyarrhythmias was counted as a VPB. Phases IA
and IB ischemic arrhythmias were defined as those occurring, respectively, before or after 10 min of coronary occlusion [25]. Ventricular fibrillation occurring in the first 3 min after reperfusion was also recorded.

**Statistical analysis**

According to the frequency and variability (mean = 74, variance = 1681) of VPBs after coronary occlusion in a previous study in the same model [11], the sample size (22 animals per group) was powered to detect, with $\alpha$- and $\beta$-probabilities of 0.05 and 0.2, respectively, a 42% reduction in the number of VPBs. Statistical analysis was performed with SPSS software (Chicago, IL). Categorical variables are described as frequencies and percentages, and continuous variables as means±SE. Differences between two independent groups were assessed by the chi-square test for categorical variables and by Student t-tests for continuous variables. General analysis of variance for repeated measures was performed to assess the effect of the loading conditions on ERP and its interaction with treatment in isolated hearts and the effect of time and treatment on hemodynamics, segment length changes, and blood test results in pigs. The

---

Fig 2. Example of monitoring in anesthetized pigs. This tracing was obtained in the ischemic period. Segment length curves clearly show an abnormal wall motion in the ischemic zone as compared to the normal motion in the control zone. ECG = Electrocardiogram; ED = End-diastole; ES = End-systole; LAD = Left anterior descending artery; LV = Left ventricle.

doi:10.1371/journal.pone.0125753.g002
effect of time and GsMtx4 on VBP incidence (square-root-transformed) throughout the occlusion period was assessed with a linear mixed effect model. The effect of treatment on ventricular arrhythmia incidence was also assessed after adjusting for relevant variables using logistic regression analyses. \( P \text{ values } < 0.05 \) were considered significant.

**Results**

**Experiments in isolated rat hearts**

Before programmed stimulation, LV developed pressure averaged 109±4 mmHg and perfusion pressure 64±1 mmHg, without differences among treated and untreated conditions. The results of these experiments are illustrated in Fig 3. In untreated hearts, the ventricular ERP decreased progressively as LVEDP increased (35±2, 32±2, and 29±2 ms at 0, 20, and 40 mmHg of LVEDP, respectively, \( P < 0.001 \)). However, when GsMtx4 was present in the perfusate, increasing the loading conditions did not affect the ERP (33±2, 33±2, and 32±2 ms, respectively, \( P = 0.002 \) for the interaction with LVEDP). Ventricular tachycardia runs in the 5 pre-defined stimulation protocols occurred with the same frequency at the 3 LVEDP values tested and their frequency was also not modified by GsMtx4. The total number of ventricular ectopic beats in these runs was also comparable at the 3 LVEDPs tested in the absence (9±5, 35±29, and 5±3, respectively) and in the presence (7±3, 8±3, and 8±3, respectively) of GsMtx4 (\( P = 0.569 \) for LVEDP, \( P = 0.436 \) for the interaction GsMtx4*LVEDP). Ventricular fibrillation was not induced.

**Hemodynamic data in anesthetized pigs**

Hemodynamic data are summarized in Table 1. At baseline, the hemodynamic parameters and LAD blood flow were within the normal range and similar in both groups, and were not modified—but for a slight increase in mean aortic pressure—after infusion of GsMtx4 or saline. Coronary occlusion induced significant (\( P < 0.001 \)) changes consisting of an increase in heart rate and LVEDP and a reduction in mean aortic pressure. Heart rate and aortic pressure increased progressively thereafter (\( P < 0.001 \)) whereas LVEDP remained unchanged (\( P = 0.488 \)). LAD blood flow during the reperfusion period was higher than at baseline (\( P < 0.001 \)). These changes were not significantly affected by treatment allocation.

**Segment length changes, blood tests and post-mortem studies in anesthetized pigs**

Segment length changes are summarized in Table 2. At baseline, EDL averaged 12.5±2.5 mm in the control zone and 13.3±2.2 mm in the LAD region. EDL and systolic shortening were not affected by the infusion of GsMtx4 or saline before ischemia. In the control zone, EDL increased slightly after occlusion and systolic shortening remained unchanged. EDL values returned to baseline throughout the experiment, without between-group differences, whereas systolic shortening experienced a minor reduction after reperfusion in controls but not in treated animals (\( P = 0.02 \)). In the LAD region, coronary occlusion induced a marked increase in EDL and abolished systolic shortening (both \( P < 0.001 \)). EDL remained stable during ischemia and declined after reperfusion to values below baseline, whereas systolic shortening persisted severely depressed throughout the experiment. No significant interactions were found between segment length changes in the LAD region and treatment allocation. The percentage of animals with greater (above the median) percent reduction in EDL in the reperfused zone 30 min after reflow, a surrogate of hypercontracture [26] was similar in treated and untreated animals (42.9 vs. 57.9%, respectively, \( P = 0.342 \)).
Fig 3. Summary of the main results of the experiments in isolated rat hearts. Top: Values of the ventricular effective refractory period in isolated rat hearts at different loading conditions and with or without GsMtx4 in the perfusate. Bottom: Number of runs of ventricular tachycardia induced by 5 stimulation protocols with coupling intervals 1 to 5 ms over the effective refractory period in isolated rat hearts. LVEDP = Left ventricular enddiastolic pressure; VT = Ventricular tachycardia.

doi:10.1371/journal.pone.0125753.g003
Table 1. Hemodynamic data in anesthetized pigs.

|                  | Baseline | Pre-CO  | 5-min CO | 15-min CO | 30-min CO | 50-min CO | 30-min R | 1-h R  | 2-h R  |
|------------------|----------|---------|----------|-----------|-----------|-----------|-----------|--------|--------|
| Heart rate, bpm  |          |         |          |           |           |           |           |        |        |
| Control          | 83±4     | 84±4    | 88±5     | 91±5      | 96±6      | 103±7     | 117±6    | 118±5  | 117±5  |
| GsMtx4           | 85±4     | 85±4    | 88±4     | 90±5      | 91±6      | 110±5     | 113±8    | 118±6  |        |
| Mean AP, mmHg    |          |         |          |           |           |           |           |        |        |
| Control          | 72±3     | 76±4    | 69±3     | 72±3      | 74±4      | 78±4      | 72±3     | 82±4   | 85±3   |
| GsMtx4           | 71±4     | 73±4    | 68±4     | 70±4      | 72±4      | 71±4      | 71±3     | 77±4   | 84±5   |
| LVEDP, mmHg      |          |         |          |           |           |           |           |        |        |
| Control          | 7±1      | 8±1     | 15±2     | 15±2      | 16±2      | 18±2      | 13±2     | 17±3   | 13±2   |
| GsMtx4           | 7±1      | 8±1     | 13±1     | 15±1      | 15±2      | 15±2      | 14±1     | 13±2   |        |
| Mean LAD flow, ml/min |     |         |          |           |           |           |           |        |        |
| Control          | 16±2     | –       | –        | –         | –         | –         | 26±3     | 31±4   | 31±4   |
| GsMtx4           | 15±2     | –       | –        | –         | –         | –         | 23±2     | 23±3   | 27±4   |

Values are means ± SE. AP = Aortic pressure, LAD = left anterior descending artery, LVEDP = Left ventricular enddiastolic pressure, CO = coronary occlusion, R = reperfusion. No significant between-group or within-group differences were observed (two-way repeated-measures analysis of variance); significance values of within-group changes are described in the text.

Table 3 summarizes blood test results. All variables remained stable throughout the experiment but for an increase in potassium levels, with no effect of GsMtx4 on any of them.

The size of the area at risk was comparable in animals receiving GsMtx4 or saline (19.2±2.8 and 18.9±2.7% of ventricular mass, respectively, P = 0.922). Infarct size was also not significantly different in both groups, either considered as absolute infarct mass (13.7±1.6 vs. 16.1±1.2 g, respectively, P = 0.235), as a percentage of ventricular mass (9.1±1.0 vs. 10.6±0.6%,

Table 2. Segment length changes in anesthetized pigs.

|                  | Baseline | Pre-CO  | 5-min CO | 15-min CO | 30-min CO | 50-min CO | 30-min R | 1-h R  | 2-h R  |
|------------------|----------|---------|----------|-----------|-----------|-----------|-----------|--------|--------|
| Nonischemic region |          |         |          |           |           |           |           |        |        |
| EDL, % of baseline|          |         |          |           |           |           |           |        |        |
| Control          | 100      | 101.3±0.5 | 103.5±0.8 | 103.6±1.0 | 103.4±1.1 | 103.0±1.0 | 98.5±0.9  | 100.0±0.8 | 99.7±1.0 |
| GsMtx4           | 100      | 100.5±0.4 | 102.4±0.6 | 102.8±0.5 | 103.1±0.8 | 103.2±0.6 | 101.8±1.1 | 101.5±1.0 | 100.6±0.7 |
| Systolic shortening, % |      |          |          |           |           |           |           |        |        |
| Control          | 22.9±1.2 | 23.3±1.2 | 23.8±1.3 | 24.0±1.3 | 23.8±1.5 | 23.8±1.3 | 22.7±1.3  | 23.4±1.1 | 21.4±1.3 |
| GsMtx4           | 22.2±1.0 | 22.0±1.0 | 22.6±1.2 | 22.7±1.2 | 23.4±1.1 | 23.9±1.1 | 23.8±1.3  | 23.5±1.3 | 22.4±1.5 |
| Ischemic region  |          |         |          |           |           |           |           |        |        |
| EDL, % of baseline|          |         |          |           |           |           |           |        |        |
| Control          | 100      | 101.1±0.7 | 111.0±1.0 | 111.3±1.0 | 110.6±1.1 | 109.8±1.4 | 84.0±2.7  | 86.8±2.6 | 89.2±2.7 |
| GsMtx4           | 100      | 100.5±0.4 | 104.7±1.5 | 112.0±1.5 | 112.1±1.5 | 109.2±1.5 | 86.4±3.1  | 87.9±3.0 | 88.2±3.2 |
| Systolic shortening, % |      |          |          |           |           |           |           |        |        |
| Control          | 28.3±1.4 | 28.2±1.3 | 0.2±0.6  | -1.1±0.7  | -1.4±0.6  | -0.3±0.4  | 1.7±0.9   | 1.4±0.7  | -0.1±0.8 |
| GsMtx4           | 29.7±1.2 | 28.4±1.8 | -0.1±0.9 | -1.4±0.9  | -1.3±0.9  | 0.5±0.7   | 2.6±1.0   | 2.3±1.1  | 1.2±1.1  |
| Systolic bulging, % |      |          |          |           |           |           |           |        |        |
| Control          | 4.0±0.5  | 4.3±0.5  | 4.6±0.4  | 2.9±0.4   | 3.3±0.7   | 3.5±0.6   | 4.7±0.8   |        |        |
| GsMtx4           | 6.0±0.7  | 6.0±0.7  | 5.6±0.6  | 3.5±0.4   | 3.2±0.9   | 3.6±0.8   | 4.0±0.9   |        |        |

Values are means ± SE. CO = coronary occlusion, EDL = Enddiastolic length, R = reperfusion. Significance values of between-group and within-group changes (two-way repeated-measures analysis of variance) are described in the text.

doi:10.1371/journal.pone.0125753.001

doi:10.1371/journal.pone.0125753.002
respectively, P = 0.208) or as a percentage of the area at risk (54.2±6.1 vs. 65.4±5.2%, respectively, P = 0.166).

### Effective refractory period and ventricular arrhythmias in anesthetized pigs

At baseline, ventricular ERP averaged 255±10 ms in controls and 277±8 ms in animals assigned to receive GsMtx4 (P = 0.134). ERP was not modified by bolus administration of either saline or GsMtx4 (286±16 and 283±8 ms, respectively, P = 0.149 for time, P = 0.337 for the interaction GsMtx4 time). Baseline ERPs were similar in animals experiencing or not ventricular fibrillation (245±35 vs. 270±6 ms, respectively, P = 0.604) or ventricular tachycardia or fibrillation (260±14 vs. 270±8 ms, respectively, P = 0.515) during the ischemic period.

The distribution of VPBs during coronary occlusion is depicted in Fig 4. The mean number of VPBs was comparable in animals treated with GsMtx4 and in those receiving saline, both in

![Graph showing distribution of ventricular premature beats](image)

**Fig 4.** Distribution of ventricular premature beats during the ischemic period in treated and untreated pigs. P values obtained with a linear mixed effect model after square-root transformation of data.

doi:10.1371/journal.pone.0125753.g004

| Table 3. Blood tests in anesthetized pigs. |
|-------------------------------------------|
|                                           |
| **Control**                              |
|                                           |
| pH                                       |
| 7.49±0.02 / 7.50±0.01                    |
| Na⁺, mmol/L                              |
| 138.2±6 / 139.5±1.0                      |
| K⁺, mmol/L                               |
| 3.54±0.10 / 4.03±0.12                    |
| HCO₃⁻, mmol/L                            |
| 31.2±1 / 32.0±0.6                        |
| Hematocrit, %                            |
| 24.8±1 / 25.8±1.2                        |
|                                           |
| **GsMtx4**                               |
|                                           |
| pH                                       |
| 7.46±0.02 / 7.51±0.02                    |
| Na⁺, mmol/L                              |
| 138.4±6 / 138.6±0.5                      |
| K⁺, mmol/L                               |
| 3.17±0.09 / 3.87±0.14                    |
| HCO₃⁻, mmol/L                            |
| 28.3±0.7 / 30.0±0.9                      |
| Hematocrit, %                            |
| 25.6±1 / 25.8±0.9                        |
|                                           |
| **P value (time/GsMtx4)**               |
| 0.127 / 0.235                            |
| 0.164 / 0.316                            |
| <0.001 / 0.266                           |
| 0.065 / 0.520                            |
| 0.173 / 0.278                            |

Values are means ± SE. P values reflect the effect of time and of GsMtx4 (interaction term, two-way repeated-measures analysis of variance).

doi:10.1371/journal.pone.0125753.t003
the IA phase (8±3 vs. 11±5, respectively, P = 0.622), in the IB phase (102±27 vs. 92±20, respectively, P = 0.771) or overall (110±28 vs. 103±21, respectively, P = 0.842).

**Fig 5** illustrates the occurrence of ventricular tachyarrhythmias during ischemia and initial reperfusion in both groups. Each line represents an animal. In cases with a very high density of ventricular tachycardia episodes not all of them could be depicted. **R** = Reperfusion.

doi:10.1371/journal.pone.0125753.g005

the IA phase (8±3 vs. 11±5, respectively, P = 0.622), in the IB phase (102±27 vs. 92±20, respectively, P = 0.771) or overall (110±28 vs. 103±21, respectively, P = 0.842).

**Fig 5** illustrates the occurrence of ventricular tachyarrhythmias during ischemia and immediately after reperfusion. Eight animals had ventricular fibrillation during ischemia, the first episode occurring 25±9 min after coronary occlusion. In comparison to controls, treated animals did not show significant reductions in the incidence of ischemic ventricular fibrillation (13.6 vs. 22.7%, respectively, P = 0.696), ventricular tachycardia (36.4 vs. 50.0%, respectively, P = 0.361), ventricular tachycardia or fibrillation (36.4 vs. 50.0%, respectively,


Discussion

The primary objective of this study was to assess the effect of intravenous administration of the selective SAC blocker GsMtx4 peptide on ischemic VPBs in swine. Compared with controls, treated animals had virtually the same number of VPBs, indicating that GsMtx4, administered under these conditions, does not suppress ventricular ectopic activity following coronary occlusion in swine. The results are compatible with some protective effect against ventricular tachycardia or fibrillation, but the study was not powered for these outcomes.

Loading conditions, ventricular refractoriness and arrhythmia inducibility in isolated rat hearts

LV dilatation decreased LV-ERP in isolated rat hearts, which concurs with previous observations in rabbit ventricles [27,28] or atria [22]. Previously, GsMTx4 non-significantly attenuated the stretch-induced decrease in ERP in isolated rabbit atria [22]. In the present study, GsMtx4 significantly altered the stretch-dependence of the ERP in isolated rat hearts, indicating that the synthetized peptide was biologically active.

LV dilatation was not associated with the incidence or duration of ventricular tachycardia episodes induced by the introduction of a single extrastimulus after continuous ventricular pacing for the determination of LV-ERP, nor did it facilitate ventricular fibrillation occurrence. These results are at variance with previous observations in rabbit ventricles [27,28] but concur with studies in canine [29]. Anyway, they made that the lack of association of GsMtx4 with ventricular tachycardia occurrence observed in our experiments was predictable.
Effects of SAC blockade on ventricular arrhythmias following coronary occlusion

Intravenous GsMtx4 did not affect the ERP in unloaded ventricles and did not suppress ventricular ectopic activity after coronary occlusion in swine. A positive result would have been expected according to previous studies suggesting a significant role of mechanical factors in the genesis of VBP during regional ischemia. In this respect, it was described that increasing the loading conditions may affect the action potential duration after coronary occlusion [14]. In isolated, swine hearts it was shown that a substantial number of VBP originate close to the ischemic border [5,6] and that their number is augmented by increasing LV volume [6]. Finally, modeling experiments of rabbit ventricles indicated that mechanical activity contributes to the origin of VBP in the ischemic border during regional ischemia [7]. The present results, however, are in line with previous studies in the same model in our laboratory showing that the dilatation of the ischemic region after coronary occlusion was not related to the number of VBP [10–13]. The reasons for the lack of association between the increase in EDL and VPB incidence following coronary occlusion in vivo are unclear. Besides the multiplicity of factors involved in arrhythmogenesis during ischemia, a possible explanation is that the increase in EDL reflects a stable, passive dilatation of the ischemic region more likely to enhance the vulnerability of the substrate than to act as a trigger. In this respect, in earlier studies demonstrating that stretch induces VBP, mechanical stress was applied in abrupt and very short pulses during early diastole [17,30], a setting very different from the stable expansion measured by EDL increase in our model. Supporting in part this interpretation, the effect of increasing the loading conditions on the incidence of ventricular arrhythmias during regional ischemia in isolated hearts was comparably greater for complex arrhythmias than for isolated VBP [6]. The magnitude and the direction of the differences in VBP density between treated and untreated animals were not homogeneous throughout the ischemic period. However, given the variability in VBP occurrence and that the effect of the treatment was not statistically significant, these differences over time may have just been the result of chance.

Our study was not powered to evaluate the effects of GsMtx4 on ventricular tachycardia or fibrillation, although the results are compatible with some protective effect of GsMtx4. In line with this, increasing LV wall stress has augmented the incidence of ventricular tachycardia or fibrillation in isolated, swine hearts [6] and regional ischemic dilatation has been associated with spontaneous ventricular tachycardia or fibrillation after coronary occlusion in anesthetized swine independently of any changes in ventricular ectopic activity [10–12]. We recently observed that distension of the ischemic region after coronary occlusion is associated with an increased susceptibility to ventricular fibrillation by programmed electrical stimulation in swine [13]. All these results strongly suggest a direct contribution of mechanical factors to the substrate of ventricular tachycardia or fibrillation during regional ischemia. This contribution is further supported by recent modeling experiments of rabbit ventricles [7] and is consistent with observations that stretch modulates ventricular fibrillation characteristics in ischemic and non-ischemic conditions [8,31].

The paucity of events made it not possible to assess the effect of GsMtx4 on post-reperfusion ventricular fibrillation, although a significant effect was not expected.

Other effects of GsMtx4 in vivo

GsMtx4 appeared to be well tolerated in vivo since it did not influence hemodynamics or segment length changes and had no effect on the laboratory parameters tested. Since this peptide reduces intracellular calcium accumulation in response to stretch [32] and targeting calcium overload has proven effective against ischemia-reperfusion injury [33], a reduction of lethal
myocardial injury after transient coronary occlusion by GsMtx4 might be expected. As administered in the present study, however, neither hypercontracture nor infarct size were significantly reduced, although a protective effect at larger doses or with a more prolonged infusion throughout the reperfusion period—since the study endpoint were ischemic arrhythmias the infusion was stopped 3 min after reflow—cannot be excluded.

Methodological considerations and limitations

To the best of our knowledge, this is the first study that has tested the effects of intravenous GsMtx4 in vivo. The dose of GsMtx4 was aimed to attain a plasma concentration above that demonstrated to protect against stretch-induced arrhythmias in isolated hearts [22]. However, the optimal dose and regime of administration of GsMtx4 to block SACs in vivo have not been established and we cannot rule out that the results would have been different with a different dose or protocol. In this respect, because of the lack of established models of acute stretch-induced electrophysiological changes in vivo [34], the biological effect of GsMtx4 was assessed in isolated rat hearts and not in the pig model, which represents a limitation. In addition, spontaneous ventricular wall distension during regional ischemia might cause a weaker SAC activation than inflating a balloon in the LV, and this might have contributed to the different responses to GsMtx4 in both models in our study. Finally in this regard, given that there are structural differences between atrial and ventricular myocardium, the concentrations of GsMtx4 necessary to block SCAs in the atria and in the ventricles might not be the same, although in our study 170 nM effectively suppressed stretch-induced changes in ventricular ERP.

GsMtx4 reached the ischemic area before ischemia but only the outer side of the ischemic border was infused after coronary occlusion. Given that GsMtx4 effects last approximately 20 min in isolated hearts after washout [21,22], effective SAC blockade inside the ischemic region during the second half of the ischemic period cannot be guaranteed. Direct infusion of the peptide inside the LAD region during coronary occlusion might have overcome this limitation. However, we chose systemic administration because a significant number of ischemic VPBs originate at the outer side of the ischemic border [6] and also because this regime is more clinically relevant than intracoronary infusion. Anyway, it seems unlikely that this limitation had influenced the lack of effect of GsMtx4 on ventricular ectopic activity given that it was observed similarly in earlier or later phases of ischemia.

As mentioned before, another limitation is that our study was not powered to detect a protective effect against ventricular tachycardia or fibrillation. For such an objective, a very large sample size (150 animals per group to detect a reduction from 25 to 12.5% in the incidence of ischemic ventricular fibrillation, or 58 animals per group to detect a reduction from 50 to 25% in the combined incidence of ventricular tachycardia or fibrillation) would be required. Although the incidence of arrhythmias tended to be higher in animals with greater ventricular distension or with a larger ischemic area, it also was not significantly reduced by GsMtx4 in these subgroups or after controlling for these variables in multivariable analyses in the overall sample. In addition, the incidence of ventricular fibrillation was lower than expected [10–12]. The fact that the magnitude of expansion of the ischemic region was somewhat lower than in previous studies in the same model that used the same experimental setting and segment length measurement methodology [10–12] may have underlain in part this observation and may explain that in the present series the ischemic increase in EDL was not significantly associated with ventricular fibrillation occurrence. Although the size of the ischemic region and serum potassium levels are well-known predictors of ischemic malignant arrhythmias, their values were quite homogeneous in our experiments and it is not surprising that they were also not significantly associated with these arrhythmias.
Conclusions

GsMtx4, administered under the present conditions, does not suppress ventricular ectopic activity following coronary occlusion in swine. The results cannot rule out some protective effect against ventricular tachycardia or fibrillation. Given the enormous impact of malignant ventricular arrhythmias in patients with acute myocardial infarction, this hypothesis should be tested in studies powered for these outcomes.

Author Contributions

Conceived and designed the experiments: JAB JI LA DGD. Performed the experiments: JAB JI LA ARS JJAB. Analyzed the data: JAB JI ARS JJAB. Contributed reagents/materials/analysis tools: LA. Wrote the paper: JAB. Critical review and approval of the manuscript: JI LA ARS JJAB DGD.

References

1. Di Diego JM, Antzelevitch C. Ischemic ventricular arrhythmias: experimental models and their clinical relevance. Heart Rhythm. 2011; 8: 1963–1968. doi: 10.1016/j.hrthm.2011.06.036 PMID: 21740880
2. Liao K, Yu L, Yang K, Saren G, Wang S, Huang B, et al. Low-level carotid baroreceptor stimulation suppresses ventricular arrhythmias during acute ischemia. PLoS One. 2014; 9: e109313. doi: 10.1371/journal.pone.0109313 PMID: 25286406
3. Calvo D, Jalife J. Mechanoelectric feedback in the ischemic myocardium: an interplay that modulates susceptibility to fibrillation. Rev Esp Cardiol. 2013; 66: 168–170. doi: 10.1016/j.rec.2012.09.017 PMID: 24775449
4. Trayanova NA, Constantino J, Gurev V. Electromechanical models of the ventricles. Am J Physiol Heart Circ Physiol. 2011; 301: H279–H286. doi: 10.1152/ajpheart.00324.2011 PMID: 21572017
5. Janse MJ, van Capelle FJL, Morsink H, Kléber AG, Wilms-Schopman F, Cardinal R, et al. Flow of “injury” current and patterns of excitation during early ventricular arrhythmias in acute regional myocardial ischemia in isolated porcine and canine hearts. Circ Res. 1980; 47: 151–165. PMID: 7397948
6. Coronel R, Wilms-Schopman FJG, deGroot JR. Origin of ischemia-induced phase 1b ventricular arrhythmias in pig hearts. J Am Coll Cardiol. 2002; 39: 166–176. PMID: 11755303
7. Jie X, Gurev V, Trayanova N. Mechanisms of mechanically induced spontaneous arrhythmias in acute regional ischemia. Circ Res. 2010; 106: 185–192. doi: 10.1161/CIRCRESAHA.109.210864 PMID: 19893011
8. Zaitsev AV, Guha PK, Sarmast F, Kolli A, Berenfeld O, Pertsov AM, et al. Wavebreak formation during ventricular fibrillation in the isolated, regionally ischemic pig heart. Circ Res. 2003; 92: 546–553. PMID: 12600877
9. Chorro FJ, Trapero I, Such-Miquel L, Pelechano F, Mainar L, Cánoves J, Tormos A, et al. Pharmacological modifications of the stretch-induced effects on ventricular fibrillation in perfused rabbit hearts. Am J Physiol Heart Circ Physiol. 2009; 297: H1860–H1869. doi: 10.1152/ajpheart.00144.2009 PMID: 19749168
10. Barrabés JA, Garcia-Dorado D, González MA, Ruiz-Meana M, Solares J, Puigfel Y, et al. Regional expansion during myocardial ischemia predicts ventricular fibrillation and coronary reocclusion. Am J Physiol. 1998; 274: H1767–H1775. PMID: 9612389
11. Barrabés JA, Garcia-Dorado D, Padilla F, Aguñó L, Trobo L, Carballo J, et al. Ventricular fibrillation during acute coronary occlusion is related to the dilation of the ischemic region. Basic Res Cardiol. 2002; 97: 445–451. PMID: 12395206
12. Barrabés JA, Garcia-Dorado D, Aguñó L, Rodríguez-Sinovas A, Padilla F, Trobo L, et al. Intracoronary infusion of Gd<sup>3+</sup> into ischemic region does not suppress phase Ib ventricular arrhythmias after coronary occlusion in swine. Am J Physiol Heart Circ Physiol. 2006; 290: H2344–H2350. PMID: 16387793
13. Barrabés JA, Figueras J, Candell-Riera J, Aguñó L, Insfran J, Garcia-Dorado D. Distension of the ischemic region predicts increased ventricular fibrillation inducibility following coronary occlusion in swine. Rev Esp Cardiol. 2013; 66: 171–176. doi: 10.1016/j.rec.2012.08.006 PMID: 24775490
14. Horner SM, Lab MJ, Murphy CF, Dick DJ, Zhou B, Harrison FG. Mechanically induced changes in action potential duration and left ventricular segment length in acute regional ischaemia in the in situ porcine heart. Cardiovasc Res. 1994; 28: 529–534. PMID: 8181042
15. Yang XC, Sachs F. Block of stretch-activated ion channels in Xenopus oocytes by gadolinium and calcium ions. Science. 1989; 243: 1068–1071. PMID: 2466333

16. Zeng T, Bett GCL, Sachs F. Stretch-activated whole cell currents in adult rat cardiac myocytes. Am J Physiol Heart Circ Physiol. 2000; 278: H548–H557. PMID: 10666087

17. Hansen DE, Borganelli M, Stacy GP Jr, Taylor LK. Dose-dependent inhibition of stretch-induced arrhythmias by gadolinium in isolated canine ventricles: evidence for a unique mode of antiarrhythmic action. Circ Res. 1991; 69: 820–831. PMID: 1873875

18. Bode F, Katchman A, Woosley RL, Franz MR. Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation. 2000; 101: 2200–2205. PMID: 10801762

19. Kiseleva I, Kamkin A, Wagner KD, Theres H, Ladhoff A, Scholz H, et al. Mechanoelectric feedback after left ventricular infarction in rats. Cardiovasc Res. 2000; 45: 370–378. PMID: 10728357

20. Caldwell RA, Clemo HF, Baumgarten CM. Using gadolinium to identify stretch-activated channels: technical considerations. Am J Physiol. 1998; 275: C619–C621. PMID: 9688617

21. Suchyna TM, Johnson JH, Hamer K, Leykam JF, Gage DA, Clemo HF, et al. Identification of a peptide toxin from Grammostola spatulata spider venom that blocks cation-selective stretch-activated channels. J Gen Physiol. 2000; 115: 583–598 [Erratum in J Gen Physiol. 2001;117: 371]. PMID: 10779316

22. Bode F, Sachs F, Franz MR. Tarantula peptide inhibits atrial fibrillation. Nature. 2001; 409: 35–36. PMID: 11343103

23. Ostrow KL, Mammoser A, Suchyna T, Sachs F, Oswald R, Kubo S, et al. cDNA sequence and in vitro folding of GsMtx4, a specific peptide inhibitor of mechanosensitive channels. Toxicon. 2003; 42: 263–274. PMID: 14559077

24. Barrabès JA, Inserte J, Mirabet M, Quiroga A, Hernando V, Figueras J, et al. Antagonism of P2Y12 or GP1b/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost. 2010; 104: 128–135. doi: 10.1160/TH09-07-0440 PMID: 20431845

25. Kaplinsky E, Ogawa S, Balke CW, Dreifus LS. Two periods of early ventricular arrhythmia in the canine acute myocardial infarction model. Circulation. 1979; 60: 397–403. PMID: 445757

26. Barrabès JA, Garcia-Dorado D, Ruiz-Meana M, Piper HM, Solares J, González MA, et al. Myocardial segment shrinkage during coronary reperfusion in situ: relation to hypercontracture and myocardial necrosis. Pflügers Arch. 1996; 431: 519–526.

27. Reiter MJ, Synhorst DP, Mann DE. Electrophysiological effects of acute ventricular dilatation in the isolated rabbit heart. Circ Res. 1988; 62: 554–562. PMID: 3342478

28. Jalal S, Williams GR, Mann DE, Reiter MJ. Effect of acute ventricular dilatation on fibrillation thresholds in the isolated rabbit heart. Am J Physiol. 1992; 263: H1306–H1310. PMID: 1415778

29. Calkins H, Maughan WL, Kass DA, Sagawa K, Levine JH. Electrophysiological effect of volume load in isolated canine hearts. Am J Physiol. 1989; 256: H1697–H1706. PMID: 2735439

30. Hansen DE, Craig CS, Hondeghem LM. Stretch-induced arrhythmias in the isolated canine ventricle: evidence for the importance of mechanoelectrical feedback. Circulation. 1990; 81: 1094–1105. PMID: 1689619

31. Hu Y, Gurev V, Constantino J, Bayer JD, Trayanova NA. Effects of mechano-electric feedback on scroll wave stability in human ventricular fibrillation. PLoS One. 2013; 8: e60287. doi: 10.1371/journal.pone.0060287 PMID: 23573245

32. Yeung EW, Whitehead NP, Suchyna TM, Gottlieb PA, Sachs F, Allen DG. Effects of stretch-activated channel blockers on [Ca\(^{2+}\)], and muscle damage in the mdx mouse. J Physiol. 2005; 562(2): 367–380. PMID: 15528244

33. Inserte J, Barrabès JA, Hernando V, Garcia-Dorado D. Orphan targets for reperfusion injury. Cardiovasc Res. 2009; 83: 169–178. doi: 10.1093/cvr/cvp109 PMID: 19351740

34. Ravelli F. Mechano-electric feedback and atrial fibrillation. Prog Biophys Mol Biol. 2003; 82: 137–149. PMID: 12722274